ATE399007T1 - Raf kinase hemmer - Google Patents

Raf kinase hemmer

Info

Publication number
ATE399007T1
ATE399007T1 AT98923601T AT98923601T ATE399007T1 AT E399007 T1 ATE399007 T1 AT E399007T1 AT 98923601 T AT98923601 T AT 98923601T AT 98923601 T AT98923601 T AT 98923601T AT E399007 T1 ATE399007 T1 AT E399007T1
Authority
AT
Austria
Prior art keywords
raf kinase
kinase inhibitor
compounds
methods
raf
Prior art date
Application number
AT98923601T
Other languages
English (en)
Inventor
Jill Wood
Hanno Wild
Daniel Rogers
John Lyons
Michael Katz
Yolanda Caringal
Robert Dally
Wendy Lee
Roger Smith
Cheri Blum
Original Assignee
Bayer Pharmaceuticals Corp
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Onyx Pharma Inc filed Critical Bayer Pharmaceuticals Corp
Application granted granted Critical
Publication of ATE399007T1 publication Critical patent/ATE399007T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT98923601T 1997-05-23 1998-05-21 Raf kinase hemmer ATE399007T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12642097P 1997-05-23 1997-05-23
US86302197A 1997-05-23 1997-05-23
PCT/US1998/010376 WO1998052559A1 (en) 1997-05-23 1998-05-21 Raf kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE399007T1 true ATE399007T1 (de) 2008-07-15

Family

ID=26824631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98923601T ATE399007T1 (de) 1997-05-23 1998-05-21 Raf kinase hemmer

Country Status (10)

Country Link
EP (1) EP0986382B1 (de)
JP (1) JP2002500650A (de)
AT (1) ATE399007T1 (de)
AU (1) AU7585598A (de)
CA (1) CA2291065C (de)
DE (2) DE986382T1 (de)
DK (1) DK0986382T3 (de)
ES (1) ES2153337T3 (de)
GR (1) GR20010300033T1 (de)
WO (1) WO1998052559A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834842T2 (de) * 1997-12-22 2007-05-10 Bayer Pharmaceuticals Corp., West Haven Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
AU2003204708B2 (en) * 1997-12-22 2006-05-25 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
NZ505844A (en) * 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
DE60026822T2 (de) * 1999-01-13 2006-08-24 Bayer Pharmaceuticals Corp., West Haven -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
CA2549558C (en) * 1999-01-13 2010-08-31 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
EP2298311B1 (de) * 1999-01-13 2012-05-09 Bayer HealthCare LLC Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
EP1157026A1 (de) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polyheterocyclische verbindungen mit entzündungshemmender wirkung
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
EE04799B1 (et) 1999-03-12 2007-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
ES2251360T3 (es) 1999-03-12 2006-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios.
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6573409B1 (en) 1999-07-02 2003-06-03 The Nutrasweet Company Process for the preparation of 3,3-dimethylbutanal
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
DE10050492A1 (de) * 2000-10-11 2002-04-25 Morphochem Ag Verfahren zur Herstellung von 5-Oxo-2,5-dihydro-furan-2-carbonsäureamiden und 6-Oxo-3,6-dihydro-2H-pyran-2-carbonsäureamiden
WO2002044156A2 (en) 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
CA2445003A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
PL208713B1 (pl) 2001-06-11 2011-05-31 Virochem Pharma Inc Związek stanowiący pochodną tiofenu, kompozycja farmaceutyczna zawierająca taki związek i jego zastosowanie
EP1709965A3 (de) * 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methode zur Behandlung von zytokinvermittelten Erkrankungen
SI1450799T1 (sl) * 2001-12-03 2007-02-28 Bayer Pharmaceuticals Corp Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
EP1534282B1 (de) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
KR20060025141A (ko) 2003-05-15 2006-03-20 아르퀼 인코포레이티드 P38의 억제제 및 이를 사용하는 방법
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
UA84156C2 (ru) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
KR20060080918A (ko) * 2003-08-15 2006-07-11 아스트라제네카 아베 치환된 티오펜 및 이의 용도
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
EP1751139B1 (de) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
RU2410384C2 (ru) 2004-06-17 2011-01-27 Цитокинетикс, Инк. Соединения, композиции и способы их использования
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP2258704A1 (de) 2004-10-19 2010-12-08 ArQule, Inc. Synthese aus Imidazooxazol- und Imidazothiazol-hemmern der P38-map-kinase
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
SG160364A1 (en) 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
EA016071B1 (ru) 2005-05-13 2012-01-30 Вирокем Фарма Инк. Соединения и способы лечения или предотвращения флавивирусных инфекций
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
JP5072595B2 (ja) 2005-08-05 2012-11-14 中外製薬株式会社 マルチキナーゼ阻害剤
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959960B1 (de) 2005-12-15 2013-04-10 Cytokinetics, Inc. Bestimmte chemische entitäten, zusammensetzungen und verfahren
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
CN102627657B (zh) * 2012-03-09 2015-01-07 苏州施亚生物科技有限公司 3-(4-甲氧基-苄基)-1h-嘧啶-2,4-二酮衍生物的合成方法
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
CN106470974B (zh) * 2014-04-17 2019-07-16 韩国巴斯德研究所 用于治疗病毒感染的化合物
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
KR102420944B1 (ko) * 2016-10-26 2022-07-15 이시하라 산교 가부시끼가이샤 3-메틸-2-티오펜카르복실산의 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61268678A (ja) * 1985-05-17 1986-11-28 バイエル・アクチエンゲゼルシヤフト 生産増進剤
US5597719A (en) * 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
EP1019040B1 (de) * 1997-05-23 2004-09-29 Bayer Corporation Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen

Also Published As

Publication number Publication date
DK0986382T3 (da) 2008-10-20
EP0986382A1 (de) 2000-03-22
EP0986382B1 (de) 2008-06-25
JP2002500650A (ja) 2002-01-08
ES2153337T1 (es) 2001-03-01
WO1998052559A1 (en) 1998-11-26
EP0986382A4 (de) 2001-04-11
DE986382T1 (de) 2001-01-25
AU7585598A (en) 1998-12-11
DE69839639D1 (en) 2008-08-07
CA2291065C (en) 2010-02-09
ES2153337T3 (es) 2008-11-01
GR20010300033T1 (en) 2001-06-29
CA2291065A1 (en) 1998-11-26

Similar Documents

Publication Publication Date Title
ATE399007T1 (de) Raf kinase hemmer
DE69831013D1 (de) Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
CY1105395T1 (el) Αναστολη της raf κινασης χρησιμοποιωντας αρυλικες και ετepοαρυλικες υποκατεστημενες ετepοκυκλικες ουριες
ATE270278T1 (de) Phthalazinone pde iii/iv hemmer
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
BR0209149A (pt) Ftalazinonas
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
DE60026350D1 (de) Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0986382

Country of ref document: EP

REN Ceased due to non-payment of the annual fee